NCT03214354View on ClinicalTrials.gov

Nonmyeloablative Stem Cell Transplant in Children with Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Sickle Cell DiseaseStem Cell Transplant ComplicationsRed Blood Cell DisorderPure Red Cell Aplasia
Interventions
DRUG

Alemtuzumab

Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days

RADIATION

Total Body Irradiation

TBI 300 cGy on Day -2

DRUG

Sirolimus

Sirolimus is used for GVHD prophylaxis

Trial Locations (1)

T3B 6A8

RECRUITING

Alberta Children's Hospital, Calgary

All Listed Sponsors
lead

University of Calgary

OTHER